Could a common blood thinner shield psoriasis Patients' arteries?
NCT ID NCT07744191
First seen Aug 04, 2026 · Last updated Aug 06, 2026 · Updated 2 times
Summary
This trial tests whether antiplatelet medications, specifically clopidogrel and aspirin, can reduce inflammation in the blood vessels of people with psoriasis or psoriatic arthritis. Participants take each drug or a placebo for four weeks, and researchers measure changes in inflammatory markers from blood vessel cells. The goal is to see if these drugs might lower the risk of atherosclerosis, a condition linked to heart disease, in this population.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- aspirin and clopidogrel
- What this could lead to
- If clopidogrel reduces blood vessel inflammation, it could point toward a way to lower heart disease risk in people with psoriasis.
- What could go wrong
- This is a small, early-stage trial measuring biological markers, not actual heart events. The effect may be modest or not translate to real-world benefits.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS (PSO) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NYU Langone Health
New York, New York, 10016, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can diabetes drugs tame joint inflammation in psoriatic arthritis?
- Can a new pill tame psoriasis? early safety trial begins
- New biologic drug aims to ease joint pain and swelling in Tough-to-Treat psoriatic arthritis
- Psoriasis patients: does your injection schedule matter?
- New psoriasis cream takes on old standby in Head-to-Head trial
- World's largest psoriasis care study launches to uncover treatment gaps